Phase III Study In Treatment-naive Adults With HIV Evaluates Efficacy And Safety Of Once Daily PREZISTA/RITONOVIR Vs. KALETRA

Results from an ongoing Phase III ARTEMIS study that examines an investigational 800mg* once daily dose of PREZISTA® (darunavir/ritonavir) versus KALETRA®1 (lopinavir/ritonavir) 400 mg/100 mg twice daily (or 800 mg/200 mg once daily depending on the local licence) in treatment-naïve adults** with HIV-1, successfully met the primary end point of non-inferiority (95% confidence internal with the lower limit for the difference in treatment response -12% or greater for HIV RNA of less than 50 copies per mL in plasma at week 48). Of the patients taking darunavir/r, 84% reached an undetectable viral load (<50 copies/mL) at week 48, compared with 78% taking lopinavir/r. read more